Oh Do Youn, Kim Jee Hyun, Lee Se Hoon, Kim Dong Wan, Im Seock Ah, Kim Tae You, Heo Dae Seog, Bang Yung Jue, Kim Noe Kyeong
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, South Korea.
Support Care Cancer. 2007 Jun;15(6):631-636. doi: 10.1007/s00520-006-0184-9. Epub 2006 Nov 11.
To better understand current practice relating to artificial nutrition/hydration in terminal cancer patients, we enrolled terminal cancer patients who were admitted at Seoul National University Boramae Hospital for supportive care only and who died with a duration of hospital stay to death of more than 1 week between 2003 and 2004. We detailed oral intake and intravenous nutrition/hydration status on admission, 1 week after admission, and 2 days before death. Administered calories and changes in these according to time and "DNR" (do-not-resuscitate) status were noted.
Of the total 165 patients, oral intake was possible in 84 patients (50.9%) on admission, in 79 patients (47.8%) on 1 week after admission, and in 29 patients (17.5%) 2 days before death (p < 0.01). Intravenous nutrition/hydration was administered to 133 patients (80.6%) on admission, to 125 patients (75.7%) at 1 week, and to 137 patients (83.0%) 2 days before death (p = 0.7). The calories administered to the patient by oral intake were 393 kcal on admission, 353 kcal 1 week after admission, and 89 kcal 2 days before death. In addition, the calories delivered by intravenous fluid were 369, 386 and 465 kcal, respectively. Near to death, calories by oral intake continuously reduced (p < 0.01) and intravenous calories continuously increased (p = 0.04), but total administered calories reduced (p = 0.03). Intravenous nutrition/hydration stopped after the attainment of the advance directive of DNR in 9% of patients.
This study showed the high prevalence of artificial nutrition/hydration, especially intravenous infusion, in Korean terminal cancer patients compared with situation in other countries. More studies are needed to verify the efficacy of artificial nutrition/hydration in terminal cancer patients.
为了更好地了解晚期癌症患者人工营养/补液的当前实践情况,我们纳入了2003年至2004年间在首尔国立大学博拉梅医院仅因支持治疗入院且住院至死亡时间超过1周的晚期癌症患者。我们详细记录了患者入院时、入院1周后以及死亡前2天的经口摄入量和静脉营养/补液情况。记录了给予的热量以及这些热量随时间和“不要复苏”(DNR)状态的变化。
在总共165例患者中,入院时84例患者(50.9%)能够经口摄入,入院1周后79例患者(47.8%)能够经口摄入,死亡前2天29例患者(17.5%)能够经口摄入(p<0.01)。入院时133例患者(80.6%)接受了静脉营养/补液,1周时125例患者(75.7%)接受了静脉营养/补液,死亡前2天137例患者(83.0%)接受了静脉营养/补液(p = 0.7)。经口摄入给予患者的热量入院时为393千卡,入院1周后为353千卡,死亡前2天为89千卡。此外,静脉输液提供的热量分别为369、386和465千卡。临近死亡时,经口摄入的热量持续减少(p<0.01),静脉热量持续增加(p = 0.04),但给予的总热量减少(p = 0.03)。9%的患者在达成DNR预先指示后停止了静脉营养/补液。
本研究表明,与其他国家的情况相比,韩国晚期癌症患者人工营养/补液,尤其是静脉输注的发生率较高。需要更多研究来验证人工营养/补液在晚期癌症患者中的疗效。